Overview

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.
Phase:
Phase 3
Details
Lead Sponsor:
Lindner Center of HOPE
Collaborators:
Eli Lilly and Company
University of Cincinnati
Treatments:
Olanzapine
Zonisamide